Oral polio vaccine stockpile modeling: insights from recent experience

References

• Fine PE, Sutter RW, Orenstein WA. Stopping a polio outbreak in the post-eradication era. Dev Biol (Basel). 2001;105:129–150.
   PubMedGoogle Scholar
• Esbitt D. The strategic national stockpile: roles and responsibilities of health care professionals for receiving the stockpile assets. Disaster Manag Response. 2003 Jul;1(3):68–70. doi: 10.1016/S1540-2487(03)00044-0
   PubMedGoogle Scholar
• Duintjer Tebbens RJ, Pallansch MA, Alexander JP, et al. Optimal vaccine stockpile design for an eradicated disease: application to polio. Vaccine. [2010 Jun 11];28(26):4312–4327. doi: 10.1016/j.vaccine.2010.04.001
   PubMed Web of Science ®Google Scholar
• Jarrett S, Pagliusi S, Park R, et al. The importance of vaccine stockpiling to respond to epidemics and remediate global supply shortages affecting immunization: strategic challenges and risks identified by manufacturers. Vaccine: X. 2021 Dec;9:100119.
   PubMedGoogle Scholar
• Thompson KM, Duintjer Tebbens RJ. Framework for optimal global vaccine stockpile design for vaccine-preventable diseases: application to measles and cholera vaccines as contrasting examples. Risk Anal. 2016 Jul;36(7):1487–1509. doi: 10.1111/risa.12265
   PubMed Web of Science ®Google Scholar
• Yen C, Hyde TB, Costa AJ, et al. The development of global vaccine stockpiles. Lancet Infect Dis. 2015 Mar;15(3):340–347. doi: 10.1016/S1473-3099(14)70999-5
   PubMed Web of Science ®Google Scholar
• Prevots DR, Burr RK, Sutter RW, et al. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. [2000 May 19];49(RR–5):1–22.
   PubMedGoogle Scholar
• Alexander L, Birkhead G, Guerra F, et al. Ensuring preparedness for potential poliomyelitis outbreaks: recommendations for the US poliovirus vaccine stockpile from the National Vaccine Advisory Committee (NVAC) and the Advisory Committee on Immunization Practices (ACIP). Archives Of Pediatrics & Adolescent Medicine. 2004 Dec;158(12):1106–1112.
   PubMedGoogle Scholar
• Jenkins PC, Modlin JF. Decision analysis in planning for a polio outbreak in the United States. Pediatrics. 2006 Aug;118(2):611–618. doi: 10.1542/peds.2005-2358
   PubMed Web of Science ®Google Scholar
• Thompson KM, Wallace GS, Tebbens RJ, et al. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. Public Health Rep. 2012 Jan;127(1):23–37. doi: 10.1177/003335491212700104
   PubMed Web of Science ®Google Scholar
• WHO. Polio vaccines: WHO position paper - June 2022. Weekly Epidemiol Rec. 2022;97(25):277–300.
   Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, et al. Expert review on poliovirus immunity and transmission. Risk Anal. 2013 Apr;33(4):544–605. doi: 10.1111/j.1539-6924.2012.01864.x
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006 Dec;26(6):1471–1505. doi: 10.1111/j.1539-6924.2006.00827.x
   PubMed Web of Science ®Google Scholar
• Platt LR, Estivariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. [2014 Nov 1];210(suppl 1):S380–9. doi: 10.1093/infdis/jiu184
   PubMedGoogle Scholar
• Duintjer Tebbens RJ, Pallansch MA, Kim JH, et al. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVdpvs). Risk Anal. 2013 Apr;33(4):680–702. doi: 10.1111/risa.12022
   PubMed Web of Science ®Google Scholar
• Konopka-Anstadt JL, Campagnoli R, Vincent A, et al. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines. 2020;5(1):26. doi: 10.1038/s41541-020-0176-7
   PubMed Web of Science ®Google Scholar
• GPEI. GPEI statement on cVDPV2 detections in Burundi and Democratic Republic of the Congo. Geneva (Switzerland): World Health Organization; 2023 [2023 Apr 25]. Available from: https://polioeradication.org/news-post/gpei-statement-on-cvdpv2-detections-in-burundi-and-democratic-republic-of-the-congo/.
   Google Scholar
• WHO. Report of the second joint meeting (hybrid) of the WHO global advisory committee on vaccine safety and the WHO advisory committee on safety of medicinal products. Wkly Epidemiol Rec. [2022 Dec 14–16] Mar 3 2023;98(9):83–92.
   Google Scholar
• Haldar P, Agrawal P, Bhatnagar P, et al. Fractional-dose inactivated poliovirus vaccine, India. Bull World Health Organ. 2019 May 1;97(5):328–334. doi: 10.2471/BLT.18.218370
   PubMed Web of Science ®Google Scholar
• Gamage D, Ginige S, Palihawadana P. National introduction of fractional-dose inactivated polio vaccine in Sri Lanka following the global “switch”. WHO South East Asia J Public Health. 2018 Sep;7(2):79–83. doi: 10.4103/2224-3151.239418
   PubMedGoogle Scholar
• Bashorun AO, Badjie Hydara M, Adigweme I, et al. Intradermal administration of fractional doses of the inactivated poliovirus vaccine in a campaign: a pragmatic, open-label, non-inferiority trial in the Gambia. Lancet Glob Health. 2022 Feb;10(2):e257–e268. doi: 10.1016/S2214-109X(21)00497-6
   PubMed Web of Science ®Google Scholar
• Okayasu H, Sein C, Chang Blanc D, et al. Intradermal administration of fractional doses of inactivated poliovirus vaccine: a dose-sparing option for polio immunization. J Infect Dis. [2017 Jul 1];216(suppl_1):S161–s167. doi: 10.1093/infdis/jix038
   PubMedGoogle Scholar
• Macklin GR, Peak C, Eisenhawer M, et al. Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): novel oral polio vaccine type 2 (nOPV2) experience. Vaccine. 2023 Apr 6;41(Suppl 1):A122–A127. doi: 10.1016/j.vaccine.2022.02.050
   PubMedGoogle Scholar
• Kalkowska DA, Wassilak SGF, Wiesen E, et al. Complexity of options related to restarting Oral Poliovirus Vaccine (OPV) in national immunization programs after OPV cessation. Gates Open Res. 2023;7:55. doi: 10.12688/gatesopenres.14511.1
   PubMedGoogle Scholar
• Yeh MT, Smith M, Carlyle S, et al. Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3. Nature. 2023 [2023 Jul 1];619(7968):135–142. doi: 10.1038/s41586-023-06212-3
   PubMed Web of Science ®Google Scholar
• Bahar MW, Porta C, Fox H, et al. Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines. NPJ Vaccines. [2021 Jan 8];6(1):5. doi: 10.1038/s41541-020-00267-3
   PubMed Web of Science ®Google Scholar
• Xu Y, Ma S, Huang Y, et al. Virus-like particle vaccines for poliovirus types 1, 2, and 3 with enhanced thermostability expressed in insect cells. Vaccine. [2019 Apr 17];37(17):2340–2347. doi: 10.1016/j.vaccine.2019.03.031
   PubMed Web of Science ®Google Scholar
• WHO. Poliomyelitis: mechanism for management of potetnial risks to eradication. Geneva (Switzerland): World Health Organization; 2008 [cited May 9, 2023]. Available from: https://polioeradication.org/wp-content/uploads/2016/07/WHA61_Resolution_English.pdf.
   Google Scholar
• WHO. Poliomyelitis. Geneva (Switzerland): World Health Organization; 2015 [cited May 9, 2023]. Available from: https://polioeradication.org/wp-content/uploads/2016/07/A68_R3-en.pdf.
   Google Scholar
• Duintjer Tebbens RJ, Sangrujee N, Thompson KM. The costs of polio risk management policies after eradication. Risk Analysis. 2006 Dec;26(6):1507–1531. doi: 10.1111/j.1539-6924.2006.00842.x
   PubMed Web of Science ®Google Scholar
• Harutyunyan V, Quddus A, Pallansch M, et al. Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal. Vaccine. [2023 Apr 6];41 (Suppl 1):A70–A78. doi: 10.1016/j.vaccine.2022.02.058
   PubMedGoogle Scholar
• GPEI. Responding to a poliovirus outbreak - part 2: protocol for poliovirus type 2. Geneva (Switzerland): World Health Organization; 2017 [cited 2023 May 10]. Available from: https://polioeradication.org/wp-content/uploads/2018/01/pol-sop-responding-polio-event-outbreak-part2-20180117.pdf.
   Google Scholar
• Duintjer Tebbens RJ, Thompson KM. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs. BMC Infect Dis. [2015 Sep 24];15(1):390. doi: 10.1186/s12879-015-1114-6
   PubMedGoogle Scholar
• Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, et al. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infecti Dis. 2016;16(1):137. doi: 10.1186/s12879-016-1465-7
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Thompson KM. Poliovirus vaccination during the endgame: insights from integrated modeling. Expert Rev Vaccines. 2017;16(6):577–586. doi: 10.1080/14760584.2017.1322514
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Thompson KM. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Expert Rev Vaccines. 2018 [2018 Aug 3];17(8):739–751. doi: 10.1080/14760584.2018.1506333.
   PubMed Web of Science ®Google Scholar
• GPEI. Polio eradication & endgame strategic Plan 2013-2018. Geneva (Switzerland): World Health Organization; 2013 [cited 2023 May 9]. Available from: http://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_A4.pdf.
   Google Scholar
• Thompson KM, Kalkowska DA. Review of poliovirus modeling performed from 2000-2019 to support global polio eradication. Expert Rev Vaccines. 2020;19(7):661–686. doi: 10.1080/14760584.2020.1791093
   PubMed Web of Science ®Google Scholar
• Kalkowska DA, Voorman A, Pallansch MA, et al. The impact of disruptions caused by the COVID-19 pandemic on global polio eradication. Vaccine. [2023 Apr 6];41 (Suppl 1):A12–A18. doi: 10.1016/j.vaccine.2021.04.026
   PubMedGoogle Scholar
• Kalkowska DA, Pallansch MA, Wassilak SGF, et al. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. Vaccine. [2023 Apr 6];41(Suppl 1):A136–A141. doi: 10.1016/j.vaccine.2021.04.061
   PubMedGoogle Scholar
• Kalkowska DA, Wassilak SGF, Pallansch MA, et al. Outbreak response strategies with type 2-containing oral poliovirus vaccines. Vaccine. [2023 Apr 6];41 (Suppl 1):A142–A152. doi: 10.1016/j.vaccine.2022.10.060
   PubMedGoogle Scholar
• Kalkowska DA, Pallansch MA, Wilkinson A, et al. Updated characterization of poliovirus outbreak response strategies for 2019-2029: impacts of the use of novel OPV2 strains. Risk Anal. 2021;41(2):329–348. doi: 10.1111/risa.13622
   PubMed Web of Science ®Google Scholar
• Kalkowska DA, Thompson KM. Expected implications of globally-coordinated cessation of serotype 3 oral poliovirus vaccine (OPV) before serotype 1 OPV. Risk Anal. 2021;41(2):312–319. doi: 10.1111/risa.13590
   PubMed Web of Science ®Google Scholar
• Kalkowska DA, Wassilak SGF, Wiesen E, et al. Coordinated global cessation of oral poliovirus vaccine use: options and potential consequences. Risk Anal. 2023 Jun 21. Online ahead of print. doi: 10.1111/risa.14158
   Web of Science ®Google Scholar
• Kalkowska DA, Wiesen E, Wassilak SGF, et al. Worst-case scenarios: modeling uncontrolled type 2 polio transmission. Risk Anal. 2023 Jun 21. Online ahead of print. doi: 10.1111/risa.14159
   Web of Science ®Google Scholar
• UNICEF Supply Division. Consultation between GPEI and poliovirus vaccine manufacturers, national authorities for containment and national regulatory authorities, Virtual meeting, 11 October 2022. 2023 [cited 2023 Feb 27]]. Available from: https://polioeradication.org/wp-content/uploads/2023/01/Annual-GPEI-Consultation-with-polio-vaccine-manufacturers-NACs-NRAsv-prepublication-version.pdf.
   Google Scholar
• World Health Organization. Global OPV stockpile strategy 2022-2026, November 2022. Geneva (Switzerland); 2023 [cited 2023 Aug 10]. https://polioeradication.org/wp-content/uploads/2023/06/Global-OPV-Stockpile-Strategy-31052023.pdf
   Google Scholar
• GPEI. Polio endgame strategy 2019-2023: eradication, integration, certification and containmen. Geneva (Switzerland): World Health Organization; 2019 [cited 2020 Jun 18]. Available from: https://apps.who.int/iris/bitstream/handle/10665/329948/WHO-Polio-19.04-eng.pdf.
   Google Scholar
• GPEI. Strategy for response to type 2 circulating vaccine-derived poliovirus 2020-2021: An addendum to the polio endgame strategy 2019-2023. Geneva (Switzerland): World Health Organization; 2020 [cited 2020 Mar 10]. Available from: http://polioeradication.org/wpcontent/uploads/2020/04/Strategy-for-the-response-to-type-2-circulating-Vaccine-DerivedPoliovirus-20200406.pdf.
   Google Scholar
• GPEI. Delivering on a promise. Polio eradication strategy 2022–2026. Geneva (Switzerland): World Health Organization; 2021 [cited 2021 Jun 18]. Available from: https://polioeradication.org/wp-content/uploads/2021/06/polio-eradication-strategy-2022-2026-pre-publication-version-20210609.pdf.
   Google Scholar
• GPEI. Library - policy and reports. Geneva (Switzerland): World Health Organization; 2023 [cited 2023 Mar 1]. Available from: https://polioeradication.org/library/.
   Google Scholar
• UNICEF. Search. New york (NY): United Nations Children’s Fund; 2023 [cited 2023 Mar 1]. Available from: https://www.unicef.org/search.
   Google Scholar
• United Nations. World population prospects 2019. (NY): United Nations, Department of Economic and Social Affairs, Population Division; 2019 [cited 2023 May 9]. Available from: https://www.un.org/development/desa/pd/news/world-population-prospects-2019-0.
   Google Scholar
• World Bank. World Bank country and lending groups. Washington DC: The World Bank; 2023 [cited 2023 May 9]. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups.
   Google Scholar
• Sriudomporn S, Watts E, Yoon Sim S, et al. Achieving immunization agenda 2030 coverage targets for 14 pathogens: projected product and immunization delivery costs for 194 countries, 2021–2030. Vaccine: X. 2023 [2023 Apr 1];13:100256.
   PubMedGoogle Scholar
• Smith G, Michelson J, Singh R, et al. Is there enough vaccine to eradicate measles? An integrated analysis of measles-containing vaccine supply and demand. J Infect Dis. 2011;204(suppl_1):S62–S70. doi: 10.1093/infdis/jir130
   PubMedGoogle Scholar
• Kalkowska DA, Badizadegan K, Thompson KM. Outbreak management strategies for cocirculation of multiple poliovirus types. Vaccine. [2023 Jun 7];41(25):3718–3727. doi: 10.1016/j.vaccine.2023.04.037
   PubMed Web of Science ®Google Scholar
• Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation. Medscape J Med. 2008;10(8):190.
   PubMedGoogle Scholar
• Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. An economic analysis of poliovirus risk management policy options for 2013–2052. BMC Infect Dis. 2015 [2015 Sep 24];15(1):389. doi: 10.1186/s12879-015-1112-8
   PubMedGoogle Scholar
• Kalkowska DA, Pallansch MA, Wassilak SGF, et al. Global transmission of live polioviruses: updated dynamic modeling of the polio endgame. Risk Anal. 2021 Feb;41(2):248–265. doi: 10.1111/risa.13447
   PubMed Web of Science ®Google Scholar
• UNICEF. Request for proposals - monovalent (Sabin) oral polio vaccine type 2 in bulk form, potential conversion into finished product and delivery, including the services for storage, management, and maintenance in a global stockpile. UNICEF Supply Division; 2020 [cited 2023 May 10]. Available from: https://www.ungm.org/Public/Notice/118260.
   Google Scholar
• WHO. Circulating vaccine-derived poliovirus. 2023. Available from: https://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/.
   Google Scholar
• WHO. Statement of the thirty-sixth meeting of the polio IHR emergency committee. Geneva (Switzerland): World Health Organization; 2023 [cited 2023 Sep 1]. Available from: https://www.who.int/news/item/25-08-2023-statement-of-the-thirty-sixth-meeting-of-the-polio-ihr-emergency-committee.
   Google Scholar
• UNICEF. Vaccine industry consultation 2022: product updates for the portfolio of polio vaccines. UNICEF Supply Division; 2022 [cited 2023 Apr 21]. Available from: https://www.unicef.org/supply/media/14136/file/Portfolio-Polio-products-Ian-Lewis-Jason-Thompson-2022.pdf.
   Google Scholar
• GPEI. Delivering on the promise of a polio free world for every child - vaccine industry consultation, September 2022. Geneva (Switzerland): Global Polio Eradication Initiative; 2022 [cited 2023 Apr 21]. Available from: https://www.unicef.org/supply/media/14131/file/Programme-Market-Update-Polio-Steven-Lauwerier-2022.pdf.
   Google Scholar
• Lewis I, Ottosen A, Rubin J, et al. A supply and demand management perspective on the accelerated global introductions of inactivated poliovirus vaccine in a constrained supply market. J Infect Dis. [2017 Jul 1];216(suppl_1):S33–s39. doi: 10.1093/infdis/jiw550
   PubMedGoogle Scholar
• Rubin J, Ottosen A, Ghazieh A, et al. Managing the planned cessation of a global supply market: lessons learned from the global cessation of the trivalent oral poliovirus vaccine market. J Infect Dis. [2017 Jul 1];216(suppl_1):S40–s45. doi: 10.1093/infdis/jiw571
   PubMedGoogle Scholar
• WHO. 14th meeting of the SAGE polio Working group - Conclusions and recommendations. Geneva (Switzerland): World Health Organization; 2017 [cited 2023 May 10]. Available from: https://terrance.who.int/mediacentre/data/sage/SAGE_Docs_Ppt_Oct2017/5_session_polio/Oct2019_session5_14th_SAGE_PolioWG.pdf.
   Google Scholar
• Duintjer Tebbens RJ, Hampton LM, Wassilak SGF, et al. Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation. J Vaccines Vaccin. 2016 Oct;7(5). doi: 10.4172/2157-7560.1000340
   Google Scholar
• GPEI. Consultation between the GPEI and polio vaccine manufacturers, national authorities for containment and national regulatory authorities. Geneva (Switzerland): Global Polio Eradication Initiative; 2022 [cited 2023 SepSep 1]. Available from: https://polioeradication.org/wp-content/uploads/2023/04/Annual-GPEI-Consultation-with-polio-vaccine-manufacturers-NACs-NRAs-V1.2-20220331.pdf
   Google Scholar
• UNICEF. Market supply and update: oral polio vaccine, bivalent (bOPV). UNICEF; 2022 [cited 2023 Apr 21]. Available from: https://www.unicef.org/supply/media/14396/file/bOPV-Poster-2022.pdf.
   Google Scholar
• GPEI. Consultation between the global polio eradication Initiative and poliovirus vaccine manufacturers, national authorities for containment and national regulatory authorities. Geneva (Switzerland): Global Polio Eradication Initiative; 2021 [cited 2023 Apr 21]. Available from: https://polioeradication.org/wp-content/uploads/2022/01/GPEI-Consultation-with-Polio-Vaccine-Manufacturers-NACs-NRAs-2021-v1.0.pdf.
   Google Scholar
• Aylward RB, Sutter RW, Heymann DL. OPV cessation–the final step to a “polio-free” world. Science. 2005 Oct 28;310(5748):625–626.
   PubMed Web of Science ®Google Scholar
• Chumakov K, Ehrenfeld E, VI A, et al. Polio eradication at the crossroads. Lancet Glob Health. 2021;9(8):E1172–5. doi: 10.1016/S2214-109X(21)00205-9
   PubMed Web of Science ®Google Scholar
• Thompson KM, Kalkowska DA, Badizadegan K. Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036. Expert Rev Vaccines. 2022 Oct;5(11):1–8. doi: 10.1080/14760584.2022.2128108
   Google Scholar
• Bart KJ, Foulds J, Patriarca P. Global eradication of poliomyelitis: benefit-cost analysis. Bull World Health Organ. 1996;74(1):35–45.
   PubMed Web of Science ®Google Scholar
• Wright PF, Kim-Farley RJ, de Quadros CA, et al. Strategies for the global eradication of poliomyelitis by the year 2000. N Engl J Med. [1991 Dec 19];325(25):1774–1779. doi: 10.1056/NEJM199112193252504
   PubMed Web of Science ®Google Scholar
• Thompson KM, Kalkowska DA. An updated economic analysis of the global polio eradication Initiative. Risk Anal. 2021 Feb;41(2):393–406. doi: 10.1111/risa.13665
   PubMed Web of Science ®Google Scholar
• Okayasu H, Sein C, Hamidi A, et al. Development of inactivated poliovirus vaccine from Sabin strains: a progress report. Biologicals. 2016 Nov;44(6):581–587. doi: 10.1016/j.biologicals.2016.08.005
   PubMed Web of Science ®Google Scholar
• Capeding MR, Gomez-Go GD, Oberdorfer P, et al. Safety and immunogenicity of a new inactivated polio vaccine made from Sabin strains: a randomized, double-blind, active-controlled, phase 2/3 seamless study. J Infect Dis. 2020;226(2):308–318. doi: 10.1093/infdis/jiaa770
   Web of Science ®Google Scholar
• Okayasu H, Sutter RW, Jafari HS, et al. Affordable inactivated poliovirus vaccine: strategies and progress. J Infect Dis. [2014 Nov 1];210(Suppl 1):S459–64. doi: 10.1093/infdis/jiu128
   PubMedGoogle Scholar
• Simizu B, Abe S, Yamamoto H, et al. Development of inactivated poliovirus vaccine derived from Sabin strains. Biologicals. 2006 Jun;34(2):151–154. doi: 10.1016/j.biologicals.2006.02.010
   PubMed Web of Science ®Google Scholar
• GPEI. Consultation with OPV/IPV manufacturers, national authorities for containment and national regulatory authorities. Geneva (Switzerland): Global Polio Eradication Initiative; 2020 [cited 2023 Apr 21]. Available from: https://polioeradication.org/wp-content/uploads/2022/01/2020-GPEI-Consultation-with-OPV-IPV-Manufacturers-NACs-NRAs.pdf.
   Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. Modeling poliovirus transmission in Pakistan and Afghanistan to inform vaccination strategies in undervaccinated subpopulations. Risk Anal. 2018 Aug;38(8):1701–1717. doi: 10.1111/risa.12962
   PubMed Web of Science ®Google Scholar
• Sharma P. Biological E, panacea to make polio vaccine. 2023 [cited 2023 May 11]. Available from: https://www.livemint.com/news/india/india-prepares-to-produce-and-stockpile-new-polio-vaccine-to-fight-vaccine-derived-polio-virus-outbreaks-globally-11683826896263.html.
   Google Scholar
• Kalkowska DA, Thompson KM. Health and economic outcomes associated with polio vaccine policy options: 2019-2029. Risk Anal. 2021 Feb;41(2):364–375. doi: 10.1111/risa.13664
   PubMed Web of Science ®Google Scholar
• Meeting of the strategic advisory group of experts on immunization, April 2017 – conclusions and recommendations. Wkly Epidemiol Rec. [2017 Jun 2];92(22):301–320.
   PubMedGoogle Scholar
• Mahmood K, Pelkowski S, Atherly D, et al. Hexavalent IPV-based combination vaccines for public-sector markets of low-resource countries. Hum Vaccin Immunother. 2013 Sep;9(9):1894–1902. doi: 10.4161/hv.25407
   PubMed Web of Science ®Google Scholar
• Olivera I, Grau C, Dibarboure H, et al. Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine. BMC Health Serv Res. 2020 [2020 Apr 9];20(1):295. doi: 10.1186/s12913-020-05115-7
   PubMed Web of Science ®Google Scholar
• Trueba G, Jeyaseelan V, Lopez L, et al. Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in ecuador-results from a cross-sectional serological survey. The Lancet Regional Health – Americas. 2022;11:11. doi: 10.1016/j.lana.2022.100235
   Google Scholar
• Thompson KM, Kalkowska DA. Reflections on modeling poliovirus transmission and the polio eradication endgame. Risk Anal. 2021 Feb;41(2):229–247. doi: 10.1111/risa.13484
   PubMed Web of Science ®Google Scholar
• Darwar R, Biya O, Greene SA, et al. Assessing country compliance with circulating vaccine-derived poliovirus type 2 outbreak response standard operating procedures: April 2016 to December 2020. Vaccine. [2023 Apr 6];41 (Suppl 1):A25–a34. doi: 10.1016/j.vaccine.2023.02.060
   PubMedGoogle Scholar
• Thompson KM, Kalkowska DA, Badizadegan K. Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation [original research]. Front Public Health. 2023 [2023 Mar 24];11:11. doi: 10.3389/fpubh.2023.1098419
   Web of Science ®Google Scholar
• Kennedy SB, Macklin GR, Mason Ross G, et al. Poliovirus antibodies following two rounds of campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence survey. Lancet Glob Health. 2023 Jun;11(6):e917–e923. doi: 10.1016/S2214-109X(23)00116-X
   PubMed Web of Science ®Google Scholar
• Thompson KM. Polio endgame complexity: updating expectations for nOPV2. Lancet Infect Dis. [2023 May 10];23(9):992–994. doi: 10.1016/S1473-3099(23)00133-0
   PubMed Web of Science ®Google Scholar
• Wilkinson AL, Zaman K, Hoque M, et al. Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial. Lancet Infect Dis. [2023 May 10];23(9):1062–1071. doi: 10.1016/S1473-3099(23)00139-1
   PubMed Web of Science ®Google Scholar
• WHO. Poliomyelitis eradication: report by the Director-General. Geneva (Switzerland): World Health Organization; 2022 [cited 2023 Mar 1]. https://apps.who.int/gb/ebwha/pdf_files/EB152/B152_18-en.pdf
   Google Scholar
• Batson A, Glassman A, Federgruen A, et al. The world needs to prepare now to prevent polio resurgence post eradication. BMJ Glob Health. 2022 Dec;7(12):e011485. doi: 10.1136/bmjgh-2022-011485
   PubMed Web of Science ®Google Scholar
• WHO. Global Action Plan for poliovirus containment, fourth edition (unedited version). Geneva (Switzerland): World Health Organization; 2022 [cited 2023 Feb 10]. Available from: https://polioeradication.org/wp-content/uploads/2022/07/WHO-Global-Action-Plan-for-Poliovirus-Containment-GAPIV.pdf.
   Google Scholar
• Duintjer Tebbens RJ, Kalkowska DA, Thompson KM. Poliovirus containment risks and their management. Future Virol. 2018;13(9):617–628. doi: 10.2217/fvl-2018-0079
   PubMed Web of Science ®Google Scholar
• Duizer E, Ruijs WL, Putri Hintaran A, et al. Wild poliovirus type 3 (WPV3)-shedding event following detection in environmental surveillance of poliovirus essential facilities, the Netherlands, November 2022 to January 2023. Eurosurveillance. 2023;28(5):2300049. doi: 10.2807/1560-7917.ES.2023.28.5.2300049
   Web of Science ®Google Scholar